Author

G. Mangiatordi

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes

The antagonism of cannabinoid 1 receptor (CB1R) signaling has demonstrated clinical efficacy in treating obesity, improving insulin resistance, enhancing cardiovascular health, and mitigating metabolic risk factors in humans. Despite these positive outcomes, the clinical use of rimonabant was limited by severe centra...

J. Azuaje, Rubén Prieto-Díaz, Claudia Gioé-Gallo et al. · ACS Omega · 0 citations

Open access Oct 2026

Molecular Dynamics Reveals a Glycan Conformation Underlying IDUA Dysfunction in Attenuated MPS I

Mucopolysaccharidosis Type I (MPS I) is a rare autosomal recessive lysosomal storage disorder caused by mutations in α‐ʟ‐iduronidase (IDUA) enzyme, a glycosylated hydrolase responsible for glycosaminoglycan (GAG) degradation. Pathogenic variants are associated with a broad clinical spectrum, from severe Hurler syndrome...

M. Papadopoulos, G. Bonapace, L. Taglietti et al. · Journal of Cellular and Mole... · 0 citations

Oct 2026

Design and Development of New Dual Target Agents, Cannabinoid Subtype 2 Receptor (CB2R) Agonists, and Fatty Acid Amide Hydrolase (FAAH) Inhibitors against Neurodegeneration

As dual modulators of Cannabinoid subtype 2 receptor (CB2R) and fatty acid amide hydrolase (FAAH)an arising therapeutic strategy against diseases based on neuroinflammationwe developed a new series of N-adamantyl-benzamides bearing an anthranilic or salicylic scaffold. Derivatives 18, 22, and 25 emerged as an inter...

Giovanni Graziano, Francesco Mastropasqua, A. Fanizzi et al. · Journal of Medicinal Chemist... · 0 citations